• 1
    Renaud, S. & M. de Lorgeril. 1992. Wine, alcohol, platelets, and the French paradox for coronary heart disease. Lancet. 339: 15231526.
  • 2
    Pace-Asciak C.R., S. Hahn, E.P. Diamandis, et al . 1995. The red wine phenolics trans-resveratrol and quercetin block human platelet aggregation and eicosanoid synthesis: implications for protection against coronary heart disease. Clin. Chim. Acta. 235: 207219.
  • 3
    Frankel E.N., A.L. Waterhouse & J.E. Kinsella. 1993. Inhibition of human LDL oxidation by resveratrol. Lancet. 341: 11031104.
  • 4
    Huang C., W.Y. Ma, A. Goranson, et al . 1999. Resveratrol suppresses cell transformation and induces apoptosis through a p53-dependent pathway. Carcinogenesis 20: 237242.
  • 5
    Potter G.A., L.H. Patterson, E. Wanogho, et al . 2002. The cancer preventative agent resveratrol is converted to the anticancer agent piceatannol by the cytochrome P450 enzyme CYP1B1. Br. J. Cancer. 86: 774778.
  • 6
    Szekeres T., K. Gharehbaghi, M. Fritzer, et al . 1994. Biochemical and antitumor activity of trimidox, a new inhibitor of ribonucleotide reductase. Cancer Chemother. Pharmacol. 34: 6366.
  • 7
    Elford H.L., M. Freese, E. Passamani, et al . 1970. Ribonucleotide reductase and cellproliferation. I. Variations of ribonucleotide reductase activity with tumor growth rate in a series of rat hepatomas. J. Biol. Chem. 245: 52285233.
  • 8
    Elford, HL, G.L. Wampler & B. van't Riet. 1979. New ribonucleotide reductase inhibitors with antineoplastic activity. Cancer Res. 39: 844851.
  • 9
    Fontecave, M., M. Lepoivre, E. Elleingand, et al . 1998. Resveratrol, a remarkable inhibitor of ribonucleotide reductase. FEBS Lett. 421: 277279.
  • 10
    Boocock, D.J., G.E. Faust, K.R. Patel, et al . 2007. Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol. Biomarkers Prev. 16: 12461252.
  • 11
    Burkon, A. & V. Somoza. 2008. Quantification of free and protein-bound trans-resveratrol metabolites and identification of trans-resveratrol-C/O-conjugated diglucuronides—two novel resveratrol metabolites in human plasma. Mol. Nutr. Food Res. 52: 549557.
  • 12
    Maier-Salamon, A., B. Hagenauer, M. Wirth, et al . 2006. Increased transport of resveratrol across monolayers of the human intestinal Caco-2 cells is mediated by inhibition and saturation of metabolites. Pharm. Res. 23: 210721015.
  • 13
    Maier-Salamon, A., B. Hagenauer, G. Reznicek, et al . 2008. Metabolism and disposition of resveratrol in the isolated perfused rat liver: role of Mrp2 in the biliary excretion of glucuronides. J. Pharm. Sci. 97: 16151628.
  • 14
    Vitrac, X. A., Desmoulière,  , B. Brouillaud, et al . 2003. Distribution of [14C]-trans-resveratrol, a cancer chemopreventive polyphenol, in mouse tissues after oral administration. Life Sci. 72: 22192233.
  • 15
    Hoshino, J., E.J. Park, T.P Kondratyuk, et al . 2010. Selective synthesis and biological evaluation of sulfate-conjugated resveratrol metabolites. J. Med. Chem. 53: 50335043.
  • 16
    Calamini, B., K. Ratia, M.G. Malkowski, et al . 2010. Pleiotropic mechanisms facilitated by resveratrol and its metabolites. Biochem. J. 429: 273282.
  • 17
    Mikulski, D. & M. Molski. 2010. Quantitative structure-antioxidant activity relationship of trans-resveratrol oligomers, trans-4,4’-dihydroxystilbene dimer, trans-resveratrol-3-O-glucuronide, glucosides: trans-piceid, cis-piceid, trans-astringin and trans-resveratrol-4’-O-beta-D-glucopyranoside. Eur. J. Med. Chem. 45: 23662380.
  • 18
    Murias, M., N. Handler, T. Erker, et al . 2004. Resveratrol analogues as selective cyclooxygenase-2 inhibitors: synthesis and structure-activity relationship. Bioorg. Med. Chem. 12: 55715578.
  • 19
    Murias, M., W. Jäger, N. Handler, et al . 2005. Antioxidant, prooxidant and cytotoxic activity of hydroxylated resveratrol analogues: structure-activity relationship. Biochem. Pharmacol. 69: 903912.
  • 20
    Miksits, M., K. Wlcek, M. Svoboda, et al . 2009. Antitumor activity of resveratrol and its sulfated metabolites against human breast cancer cells. Planta Med. 75: 12271230.
  • 21
    Bader, Y., S. Madlener, S. Strasser, et al . 2008. Stilbene analogues affect cell cycle progression and apoptosis independently of each other in an MCF-7 array of clones with distinct genetic and chemoresistant backgrounds. Oncol. Rep. 19: 801810.
  • 22
    Saiko, P., M. Pemberger, Z. Horvath, et al . 2008. Novel resveratrol analogs induce apoptosis and cause cell cycle arrest in HT29 human colon cancer cells: inhibition of ribonucleotide reductase activity. Oncol. Rep. 19: 16211626.
  • 23
    Fritzer-Szekeres, M., I. Savinc, Z. Horvath, et al . 2008. Biochemical effects of piceatannol in human HL-60 promyelocytic leukemia cells—synergism with Ara-C. Int. J. Oncol. 33: 8878892.
  • 24
    Horvath, Z., S. Marihart-Fazekas, P. Saiko, et al . 2007. Novel resveratrol derivatives induce apoptosis and cause cell cycle arrest in prostate cancer cell lines. Anticancer Res. 27: 34593464.
  • 25
    Vo, T.P., S. Madlener, Z. Bago-Horvath, et al . 2009. Pro- and anti-carcinogenic mechanisms of piceatannol are activated dose-dependently in MCF-7 breast cancer cells. Carcinogenesis 22: 845852.
  • 26
    Murias, M., M.W. Luczak, A. Niepsuj, et al . 2008. Cytotoxic activity of 3,3’,4,4’,5,5’-hexahydroxystilbene against breast cancer cells is mediated by induction of p53 and downregulation of mitochondrial superoxide dismutase. Toxicol. In Vitro. 22: 13611370.
  • 27
    Horvath, Z., P. Saiko, C. Illmer, et al . 2005. Synergistic action of resveratrol, an ingredient of wine, with Ara-C and tiazofurin in HL-60 human promyelocytic leukemia cells. Exp. Hematol. 33: 329335.
  • 28
    Horvath, Z., M. Murias, P. Saiko, et al . 2006. Cytotoxic and biochemical effects of 3,3’,4,4’,5,5’-hexahydroxystilbene, a novel resveratrol analogue in HL-60 human promyelocytic leukemia cells. Exp. Hematol. 34: 13771384.
  • 29
    Wachek, V., Z. Horvath, S. Strommer, et al . 2005. Resveratrol analogue M8 chemosensitizes malignant melanoma to dacarbacin in vivo. Clin. Cancer Res. Part 2(Suppl S 11): 8971S8971S.
  • 30
    Paulitschke, V., N. Schicher, T. Szekeres, et al . 2010. 3,3’,4,4’,5,5’-hexahydroxystilbene impairs melanoma progression in a metastatic mouse model. J. Invest. Dermatol. 130: 16681679.